PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMónica Tang, Michael Friedländer, Rachel O’Connell et al.|Gynecologic Oncology|2019Cited by 88
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey‐Sei Kok, Rachel O’Connell, Peter Grant et al.|Journal of Gynecologic Oncology|2019Cited by 26
Paragon (ANZGOG-0903)Anthony Bonaventura, Michael Friedländer, Rachel O’Connell et al.|International Journal of Gynecological Cancer|2017Cited by 22
Genomic Therapy Matching in Rare and Refractory CancersFrank P. Lin, Emily Collignon, Jayesh Desai et al.|JAMA Oncology|2026Cited by 6